Comparing the Ketogenic Effect of Coconut Oil and Different MCTs

Healthy Adults Clinical Trial

— MCT-Coco  

Official title:

Comparing the Ketogenic Effect of Coconut Oil and Different Medium-chain Triglycerides

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02679222
• Other study ID #: 2016-541
• Status: Completed
• Phase: N/A
• Start date: June 2015
• Est. completion date: March 1, 2017

Study information

• Verified date: March 2020
• Source: Université de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to compare the ketogenic effect of coconut oil and three MCT oils (60-40 , tricaprylin and triheptanoate) on the production of ketones in healthy adults. Each oil are evaluated individually or in combination over a 8h-period during which repeated blood sampling is performed.

Description:

The study is composed of eight successive visits. Each visit consists of the consumption of one individual oil or a mixture of oils (20 g of coconut oil or 10 g of coconut oil + 10 g of MCT 60-40 or 20 g MCT 60-40 or 10 g coconut oil + 10 g tricaprylin or 20 g tricaprylin or 10 g coconut oil + 10 g triheptanoate or 20 g triheptanoate) and a 8h follow-up during which repeated blood samples are taken for laboratory analysis (plasma beta-hydroxybutyrate, acetoacetate, glucose, free fatty acids, triglycerides, total cholesterol, lactate and insulin).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 1, 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy adult over 18 y old.

Exclusion Criteria:

• Fasting plasma glucose =7.0 mM (diabetics or pre-diabetics);

• Smoking

• Clinically-significant gastro-intestinal disease/conditions.

• Clinically-significant liver disease/dysfunction.

• Clinically-significant cardiac disease/conditions.

• Clinically-significant abnormal coagulation.

• Taking a medication that could affect lipid and glucose metabolism

• Hypertension

• Pregnancy or breastfeeding

• Exercising more than 3 times a week

Related Conditions & MeSH terms

• Healthy Adults

Intervention

Dietary Supplement:
• Coconut oil
20 g of coconut oil
• Coconut oil + MCT
10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
• MCT
20 g of MCT (60 of C8+40 of C10)
• Coconut oil + tricaprylin
10 g coconut oil + 10 g tricaprylin
• Tricaprylin
20 g tricaprylin
• Tricaprin
20 g tricaprin
• Control
No supplement taken on this visit

Locations

Country	Name	City	State
Canada	Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)	Sherbrooke	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Université de Sherbrooke

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma Ketone Concentrations	Total ketones = Plasma acetoacetate (µmol/L) + beta-hydroxybutyrate (µmol/L) measured over a 8 hour period (i.e. daily mean).; Samples are taken every 30 minutes on a 8 hours period. The mean is reported here.	8 hours
Secondary	Plasma Acetoacetate/Beta-hydroxybutyrate Ratio	Plasma ratio of acetoacetate (µmol/L)/ beta-hydroxybutyrate (µmol/L) measured over a 8 hour period (i.e area-under-the-curve over 8 hours).	8 hours